Lv21
136 积分 2021-02-11 加入
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
3天前
已完结
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
3天前
已完结
NAFLD and diabetes mellitus
5天前
已完结
Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach
6天前
已完结
Mortality for Any Hepatic Cause in People With Diabetes Compared to the Non‐Diabetic Population. A 10‐Year‐Observational Study
6天前
已完结
Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions
6天前
已完结
Referral to hepatologists or a second-line examination requirement is common in patients with type 2 diabetes mellitus
6天前
已完结
Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice
6天前
已完结
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies
6天前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study
6天前
已完结
皖公网安备34019202002308
